AI-Powered trial asks: does adding a second drug cut heart failure risk?
NCT ID NCT07719621
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This study uses computer simulations to compare two treatment strategies for people with chronic kidney disease and type 2 diabetes. Researchers will model whether adding empagliflozin to finerenone reduces heart failure, hospitalizations, and cardiovascular death more than finerenone alone. No human participants are involved — artificial intelligence recreates a large virtual population based on real clinical data.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of finerenone and empagliflozin
- What this could lead to
- If the combination outperforms finerenone alone, it could point to a more effective treatment strategy for preventing heart failure in people with kidney disease and diabetes.
- What could go wrong
- This is a computer simulation, not a real-patient trial, so results may not fully reflect real-world outcomes. The findings depend on the accuracy of the underlying data and assumptions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CKD - CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Kidney clues may predict eye swelling after cataract surgery in diabetes patients
- Scientists hunt for hidden fat molecules that sabotage insulin
- Can a pharmacist check-in boost medication adherence in diabetes and kidney disease?
- New oral diabetes drug shows promise in early safety trial
- Could a simple breathing exercise ease pain and anxiety during nerve testing?
- New injectable drug aims to tame blood sugar in type 2 diabetes